Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Nicole S. White, the Chief Manufacturing Officer at Assembly Biosciences, Inc. (NASDAQ:ASMB), recently sold shares of the company’s common stock amid a challenging period for the company’s stock, which has declined over 16% in the past week. According to a filing with the Securities and Exchange Commission, White sold 197 shares on March 31, 2025, at an average price of $9.8481 per share, totaling approximately $1,940. InvestingPro analysis suggests the stock is currently undervalued, despite trading near its 52-week low of $9.56. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by the company’s Compensation Committee. Following this sale, White retains ownership of 11,674 shares.
In a separate transaction, White was granted stock options for 20,400 shares on March 29, 2025. These options have an exercise price of $10.62 per share and will vest over four years, contingent on continued service.
In other recent news, Assembly Biosciences has initiated a Phase 1a clinical trial for ABI-6250, a potential oral treatment for chronic hepatitis delta virus (HDV) infection. This trial aims to evaluate the safety and pharmacokinetics of the drug, with results anticipated in the third quarter of 2025. In another development, the company reported positive interim results from its Phase 1a study of ABI-1179, a candidate for treating recurrent genital herpes, indicating the potential for once-weekly dosing. Assembly Biosciences plans to advance ABI-1179 into the Phase 1b portion of the study, with interim data expected in fall 2025. Additionally, Assembly Biosciences has extended its sublease for office and laboratory space in South San Francisco through September 2029, securing a strategic location for its operations. The lease agreement with Arsenal Biosciences includes escalating rent payments starting in 2025. These developments underscore Assembly Biosciences’ ongoing efforts in advancing treatments for viral diseases and maintaining its presence in the biotech hub.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.